T0	Participants 63 151	postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy]
T1	Participants 319 426	postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT).
T2	Participants 435 563	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin
T3	Participants 674 711	Two hundred and twenty-eight patients
T4	Participants 1336 1348	136 patients
T5	Participants 2014 2033	GG or GA genotypes.
T6	Participants 2092 2117	patients with AA genotype
T7	Participants 2446 2499	postoperative stage II and III rectal cancer patients